Navigation Links
Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use
Date:3/2/2012

ANN ARBOR, Mich., March 2, 2012 /PRNewswire/ -- Rubicon Genomics, Inc., a company developing and commercializing sample-specific pre-analytical processes to improve the capabilities and performance of DNA and RNA analytical platforms, today announced that it has selected Velesco Pharmaceutical Services to manufacture the TransPLEX® kits it will be supplying for use with Agendia's breast cancer diagnostics.  Velesco is a provider of analytical method development, drug formulation, stability testing and consulting services to biotech and pharmaceutical companies. It operates a 10,000 square foot cGMP manufacturing facility in Kalamazoo, Michigan.

"We are delighted to have found a highly qualified manufacturing partner located near our headquarters in Ann Arbor," commented James Koziarz, CEO of Rubicon. "Velesco's cGMP facility and quality processes are first-rate; its quality track record is impeccable and it has the formulation, fill and finishing expertise we need. Velesco provides us an immediate pathway to cGMP kits for diagnostic use and it has the capacity to rapidly expand cGMP production as sales of our diagnostic kits ramp up. We look forward to a mutually beneficial relationship as we grow our clinical diagnostics business."

Rubicon recently announced a clinical supply agreement with molecular diagnostics firm Agendia for the company's TransPLEX whole genome RNA amplification technology. Agendia is using Rubicon's kits to facilitate the analysis of FFPE (formalin-fixed, paraffin-embedded) patient samples for use with its Symphony™ breast cancer diagnostics. cGMP production of the TransPLEX kits is required as part of the FDA's 510(K) clearance process for the Symphony tests.

"We are pleased to be able to provide high quality cGMP manufacturing services to Rubicon as they expand into the clinical diagnostics arena," said Velesco Chief Operating Officer and co-founder Gerry Cox. "The availa
'/>"/>

SOURCE Rubicon Genomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
2. Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
3. Synthetic Genomics, Inc. and Integrated DNA Technologies, Inc. Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology
4. Smartphone Technology Meets Personalized Medicine in Everist Genomics CardioDefender Diagnostic System
5. AccuGenomics to Attend OneMedForum with Standardized Gene Expression Tests for Leukemia and Lung Cancer
6. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
7. Everist Genomics to Launch CardioDefender: Worlds Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians
8. Everist Genomics Announces Acquisition of Angiologix, Inc.
9. Synthetic Genomics Vaccines, Inc. Hires Vaccine Executive Sammy J. Farah as President
10. Cancer Game Changers: Genomics, Smarter Medicine, Care Coordination Comprise Medcos Advanced Oncology Solutions™
11. Everist Genomics Announces New Data on OncoDefender™- CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Pa. , May 4, 2015 DePuy ... Dura Repair, the first commercially available biosynthesized dural ... Synthes CMF is a part of the DePuy Synthes ... is a tissue membrane that covers and protects the ... be cut to allow surgeons to access the brain. ...
(Date:5/4/2015)... ANGELES , May 4, 2015 Former ... FOX News online last week where he discussed Theradome™, ... to be FDA-cleared. The FOX segment shows firsthand how, ... and affordable hair loss solution that will not require ... stimulates the mitochondria at the base of the hair ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ ... announced that it intends to dividend to its stockholders ... of a definitive licensing agreement to license its RapidMist™ ... ) (OTCQB:SMFI). As announced on April 23, ... in respect of the licensing of its RapidMist™ buccal ...
Breaking Medicine Technology:DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5
... Aug. 21 Genetic testing can be,used to ... anticoagulant, according to research published in the,September 1, ... American Society of,Hematology. This result represents one of ... to guide personal medical care., Because individuals ...
... Randomized, Double-Blind Study Targets Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that the ... confirmatory Phase 3 trial of Genasense,(oblimersen sodium) ... as,AGENDA, is a randomized, double-blind, placebo-controlled study ...
Cached Medicine Technology:Genetics Determine Optimal Drug Dose of Common Anticoagulant 2Genetics Determine Optimal Drug Dose of Common Anticoagulant 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
(Date:5/4/2015)... HHT is a rare but cruel ... it can have seemingly mild symptoms like frequent nosebleeds, ... Hereditary Hemorrhagic Telangiectasia (HHT) is a hereditary disorder resulting ... capillary connections between an artery and a vein. These ... but may also be present in the lungs, brain ...
(Date:5/4/2015)... New York (PRWEB) May 04, 2015 ... as $2.4 billion to settle thousands of Actos lawsuits ... diabetes medication increases the risk that a patient will ... on April 28th, if 95% of those eligible for ... resolve nearly 9,000 bladder cancer cases currently pending in ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 “ LiveSchool ... monthly AppWatch, which takes a look at the latest ... and Windows. Joe Toohey, the host of AppWatch and ... viewers how this application allows teachers to reward students ... than some realize, especially in the classroom. And ...
(Date:5/4/2015)... May 04, 2015 Baptist Medical ... Stroke Association’s Get With The Guidelines®-Stroke Gold Plus ... Honor Roll. The award recognizes the hospital’s commitment ... the most appropriate treatment according to nationally recognized, ... , To receive the Gold Plus Quality Achievement ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic ... While the World Cup is the most known soccer ... the International Champions Cup is one of the biggest tournaments ... record for soccer in the United States set when Manchester ... University of Michigan. This year, the defending champion Manchester United ...
Breaking Medicine News(10 mins):Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4
... , ... Strong Backbone for Victory: Cortical Concepts Wins ,Wharton Business Plan Competition Michelson Grand ... “People’s Choice” Award with Private Sales for Co-eds, , ... Philadelphia, PA (PRWEB) April 29, ...
... ... Science and Technology Policy, will bring together leaders in open innovation , ... Washington, DC (Vocus) -- This ... Grant Making”, a public-private strategy session jointly hosted by the White House Office on ...
... Athens, Ga. A team of researchers at the University ... the next five years from the National Institutes of Health ... may prevent drug abuse relapse. "Drug abuse is ... aspects of treating addiction is preventing the relapse caused by ...
... ... awarded a $4.2 million grant from the Ontario Ministry of Research and Innovation’s Biopharmaceutical ... expansion of its bio-manufacturing facility in Mississauga, Ontario, Canada. , ... Toronto, ON (Vocus) April 30, 2010 -- ...
... how the brain communicates with limbs, researcher says , THURSDAY, ... a phenomenon known as mirror movements has been identified by ... move one side of their body without moving the other. ... the same movement occurs unintentionally in the left hand. , ...
... ... has developed a unique caregiver testing program to measure the preparedness of home care ... ... 29, 2010 -- The National Private Duty Association (NPDA), a non-profit organization comprised of ...
Cached Medicine News:Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 2Health News:Wharton Business Plan Competition Michelson Grand Prize Winners Announced 3Health News:Prize4Life Featured in Major Innovation/Prize National Conference 2Health News:Prize4Life Featured in Major Innovation/Prize National Conference 3Health News:UGA, Emory to study how exercise may prevent drug abuse relapse 2Health News:Therapure Awarded $4.2 Million BIP Grant from the Ontario Government 2Health News:Scientists Find Cause of Involuntary Mirror Movements 2Health News:Association Advocates Testing for Home Care Workers 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: